Drug-Induced Immune Hemolytic Anemia Market Overview (2023 to 2033)
The drug-induced immune hemolytic anemia market is estimated to secure a valuation of US$ 7.8 billion in 2023 and is estimated to rise to US$ 13.4 billion by 2033. The market is anticipated at a CAGR of 5.6% during the forecast period. The factors accelerating the demand for drug-induced immune hemolytic anemia are as follows-
The rapid growth of the biotechnology
Increased drug discovery and clinical research
The rising prevalence of the chronic disorder
Rising investments in research and development activity
Increased awareness about rare diseases and disorders
Increasing advancement in clinical pharmacology
Increased prevalence of adverse drug reaction
North America dominates the drug-induced immune hemolytic anemia market
Data Points
Key Statistics
Expected Market Value in 2023
US$ 7.8 billion
Projected Market Value in 2033
US$ 13.4 billion
Growth Rate (2023 to 2033)
CAGR of 5.6%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What is driving growth of the Market for Drug-Induced Immune Hemolytic Anemia?
The increasing prevalence of autoimmune disorders is expected to drive market growth. Some of the drugs that can cause drug-induced immune hemolytic anemia include Cephalosporins, Dapsone, Levodopa, Methyldopa, and Levofloxacin.
The advancement in technology is one of the major factors that is playing a crucial role in driving the growth of the drug-induced immune hemolytic anemia market. The market is highly influenced by increased R&D activities for disease therapeutics, increased pharmaceutical production capacity, and increased collaboration for product development.
Other significant factors influencing the growth of the drug-induced immune hemolytic anemia market are increased healthcare spending and increased government funding in the healthcare system.
Regional Analysis of Drug-Induced Immune Hemolytic Anemia Market
North America is expected to account for a significant share of the drug-induced immune hemolytic anemia market during the forecast period owing to the increased healthcare spending in the region. Additionally, the increased number of clinical trials in the region is supporting the market growth during the forecast period.
The drug-induced immune hemolytic anemia market in Europe is witnessing significant growth in recent years. The increasing prevalence of disease and increased healthcare spending in the region drive market growth.
Asia Pacific is expected to be the fastest-growing region in drug-induced immune hemolytic anemia market is projected to grow in near future owing to the developing healthcare sector and rising government initiatives. Also, the growing R&D activities in healthcare and increased drug discovery and antibody development in the region drive market growth.
Find your sweet spots for generating winning opportunities in this market.
How Competitive is the Market?
Some of the leading players operating in the drug-induced immune hemolytic anemia market are ARUP laboratories, Cyprotex, Creative Biolabs, Machaon Diagnostics, F-Hoffman LaRoche Ltd, Baxter International, Pfizer Inc, Zydus Cadila, Amneal Pharmaceutical, Incyte Corp among others.
The drug-induced immune hemolytic anemia market is expected to grow in the coming years. The increasing demand for effective drugs and an increasing number of clinical hemolysis are expected to drive market growth during the forecast period. Several start-ups have entered the drug-induced immune hemolytic anemia market with innovative products with the use of new technology.
Market players are focusing on strategic activities to increase their market share. The major players in the market are using different strategies like acquisitions, mergers, and partnerships to increase their brand presence. Some of the developments from the market are listed below
In September 2022 - Nanospot.ai announced that it has entered into a commercial & distribution agreement with Opto.
Founded in 2020 - Taxon therapeutics is the developer of rare autoimmune disease therapies. Also, the company focuses on the development and commercialization of recombinant therapeutic proteins for rare autoimmune diseases. They have designed Tax-01 for the treatment of adults with autoimmune hemolytic anemia, a severe and rare disorder.
According to the latest research by FMI, Drug-Induced Immune Hemolytic Anemia is set to witness a growth CAGR of 8.4% during the year 2023 to 2033. The drug-induced immune hemolytic anemia is a rare cause of anemia often associated with poor outcomes including organ failure and even death.
The development of drug-induced immune hemolytic anemia is principally due to antibody development. The drug-induced immune hemolytic anemia market is expected to grow at a moderate pace due to the development and discovery of new drugs and the rising application of pharmacovigilance for drug imputability. The most common agents for drug-induced immune hemolytic anemia are cephalosporin and penicillin.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
What is Driving Demand for Drug-Induced Immune Hemolytic Anemia?
The number of drugs and their suggested mechanisms associated with drug-induced immune hemolytic anemia have witnessed a significant change over the past 4 decades in terms of number of implicated drugs. According to the American Society of Hematology, a reported number of 125 drugs are associated with drug-induced immune hemolytic anemia as per 2017 data of reviewed publications.
The three groups of drugs identified as predominant were antimicrobials which accounted for 42% of the implicated drugs, anti-inflammatory (15%) and anti-neoplastics (11%). The advancements in clinical pharmacology and the increasing number of reviewed case-based studies on the cause and mechanisms of drug-induced immune hemolytic anemia have resulted as drivers in case identification and timely drug withdrawal and hence are set to increase the business growth.
Which factors are likely to augment growth of Drug-Induced Immune Hemolytic Anemia?
The clinical expression of drug-induced immune hemolytic anemia is generally mild, but it is also witnessed to develop into acute severe hemolytic anemia and even death. The increasing number in the reports of second and third generation cephalosporin which lead to clinical hemolysis are set to act as augmentative factors for the drug-induced immune hemolytic anemia.
USA and Canada Drug-Induced Immune Hemolytic Anemia Outlook
The principal cases of drug-induced immune hemolytic anemia are identified after post-operative conditions. The region of North America holds a significant share in the identification and measures for mitigation and improvement of patient health during this period and will continue to do so over the forecast period.
This is facilitated by the presence of advanced healthcare infrastructure, robust pharmacovigilance programs and high participation of providers in clinical programs on drug-induced immune hemolytic anemia. The American Association of Blood Banks is an active moderator of drug-induced immune hemolytic anemia market.
Europe Demand Outlook for Drug-Induced Immune Hemolytic Anemia
The outlook for drug-induced immune hemolytic anemia in the European region is expected to show a moderate influence over the forecast period. This is associated with the development of appropriate clinical guidelines by British Society for Hematology and management of drug-induced immune hemolytic anemia in post-operative situations.
Who are the Key Manufacturers and Suppliers of Drug-Induced Immune Hemolytic Anemia?
The key companies operating in Drug-Induced Immune Hemolytic Anemia are
ARUP Laboratories
Cyprotex
Creative Biolabs
machaon diagnostics
F. Hoffmann-La Roche Ltd.
Baxter International Inc.
Pfizer Inc
Zydus Cadila
Amneal Pharmaceuticals Inc
Incyte Corp
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
